Intra-Cellular Therapies, Inc.
ITCIDelisted Apr 2, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001567514
Intra-Cellular Therapies, Inc. was delisted on Apr 2, 2025; its insiders filed their last Form 4 on Apr 2, 2025; 395 institutions reported holding it in 13F filings for Q1 2025, worth $13.6B in total; Soros Fund Management was the only superinvestor holding it.
Q2 2021 vs. Q1 2021
How the institutions holding Intra-Cellular Therapies, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 170 | 187 | +17 |
| Shares | 68.0M | 67.0M | −952.0K (−1.4%) |
| Value | $2.30B | $2.74B | +$431.0M (+18.7%) |
New holders (31)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (14)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Woodline Partners LP | 294,285 | $9.98M |
| Assenagon Asset Management S.A. | 208,301 | $7.07M |
| California Public Employees Retirement System | 124,863 | $4.24M |
| Pictet Asset Management Ltd | 110,267 | $3.74M |
| Altium Capital Management LP | 88,326 | $3.00M |
| Foundry Partners, LLC | 21,405 | $726.0K |
| Blueshift Asset Management, LLC | 13,535 | $459.0K |
| Two Sigma Investments, LP | 10,587 | $359.0K |
| Man Group plc | 10,179 | $345.0K |
| Gyon Technologies Capital Management, LP | 9,242 | $314.0K |
| Gsa Capital Partners LLP | 9,216 | $313.0K |
| Simplex Trading, LLC | 5,758 | $195.0K |
| Point72 Hong Kong Ltd | 1,316 | $45.0K |
| Meridian Wealth Partners, LLC | 16 | $1.00K |